By Dean Seal


Shares of Argenx dropped after the company said a study of its treatment for primary immune thrombocytopenia didn't meet its primary or secondary endpoints.

The stock fell 10% to $445 in premarket trading. Shares had gained 31% year-to-date when the market closed Monday.

The immunology company said early Tuesday morning that its study evaluating Vyvgart Hytrulo didn't meet the primary endpoint of a sustained platelet count response in patients with chronic primary immune thrombocytopenia, an autoimmune disorder.

"This is not the outcome we had hoped for patients," Chief Medical Officer Luc Truyen said.


Write to Dean Seal at


(END) Dow Jones Newswires

November 28, 2023 06:48 ET (11:48 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
argenx (NASDAQ:ARGX)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 2월(2) 2024 argenx 차트를 더 보려면 여기를 클릭.
argenx (NASDAQ:ARGX)
과거 데이터 주식 차트
부터 2월(2) 2023 으로 2월(2) 2024 argenx 차트를 더 보려면 여기를 클릭.